MEDICAL CHRONICLE DECEMBER 2018 CPD 3 of 3: Recently the DECLARE trial was published evaluating in a randomised, double-blind, multinational, placebo- controlled trial, the effect of Dapagliflozin on safety and efficacy for macrovascular and microvascular outcomes.
Globally the prevalence of heart failure is about one in 25 of the general population with increasing prevalence with increasing age.
Current recommended treatment for heart failure: Angiotensin-converting enzyme inhibitor (ACE-Inhibitors) or Angiotensin-receptor blockers (ARB), beta-blockers (Carvedilol, Bisoprolol and Metoprolol) and mineralocorticoid receptor antagonists.
As measured over the last two decades, the mortality from cardiovascular disease (CVD) has declined by about 50% and at least half of this decline has been attributed to the use of evidence-based medication.
Heart failure with reduced ejection fraction has shown improved outcomes with evidence-based treatment but heart failure with preserved ejection fraction has not shown any improved outcomes with treatment demonstrating our lack of effective therapies for this condition.
Continuing on from Manifestations of the Metabolic Syndrome: Part 1, which appeared in the February issue of Medical Chronicle, which was all about diagnostic numbers, we look further at pathophysiology, progression, clinical presentations, prevention and practical management of the metabolic syndrome (Met-S).